SAB Biotherapeutics (SABS) Competitors $3.88 +0.62 (+19.02%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SABS vs. RGLS, AGEN, FBIO, BOLT, CRIS, MTEM, AMGN, VRTX, GILD, and REGNShould you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Regulus Therapeutics (RGLS), Agenus (AGEN), Fortress Biotech (FBIO), Bolt Biotherapeutics (BOLT), Curis (CRIS), Molecular Templates (MTEM), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "biotechnology" industry. SAB Biotherapeutics vs. Regulus Therapeutics Agenus Fortress Biotech Bolt Biotherapeutics Curis Molecular Templates Amgen Vertex Pharmaceuticals Gilead Sciences Regeneron Pharmaceuticals Regulus Therapeutics (NASDAQ:RGLS) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking. Do analysts recommend RGLS or SABS? Regulus Therapeutics presently has a consensus price target of $10.80, indicating a potential upside of 624.83%. SAB Biotherapeutics has a consensus price target of $12.40, indicating a potential upside of 219.59%. Given Regulus Therapeutics' higher probable upside, analysts clearly believe Regulus Therapeutics is more favorable than SAB Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regulus Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83SAB Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, RGLS or SABS? Regulus Therapeutics has higher earnings, but lower revenue than SAB Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegulus TherapeuticsN/AN/A-$30.04M-$1.26-1.18SAB Biotherapeutics$2.24M15.99-$42.19MN/AN/A Does the media favor RGLS or SABS? In the previous week, Regulus Therapeutics had 5 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 5 mentions for Regulus Therapeutics and 0 mentions for SAB Biotherapeutics. Regulus Therapeutics' average media sentiment score of 0.44 beat SAB Biotherapeutics' score of -1.00 indicating that Regulus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Regulus Therapeutics Neutral SAB Biotherapeutics Negative Do insiders & institutionals believe in RGLS or SABS? 92.4% of Regulus Therapeutics shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 4.4% of Regulus Therapeutics shares are owned by insiders. Comparatively, 26.5% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in RGLS or SABS? Regulus Therapeutics received 463 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 81.25% of users gave SAB Biotherapeutics an outperform vote while only 63.75% of users gave Regulus Therapeutics an outperform vote. CompanyUnderperformOutperformRegulus TherapeuticsOutperform Votes48963.75% Underperform Votes27836.25% SAB BiotherapeuticsOutperform Votes2681.25% Underperform Votes618.75% Which has more risk & volatility, RGLS or SABS? Regulus Therapeutics has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Is RGLS or SABS more profitable? Regulus Therapeutics has a net margin of 0.00% compared to SAB Biotherapeutics' net margin of -1,450.14%. Regulus Therapeutics' return on equity of -55.47% beat SAB Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Regulus TherapeuticsN/A -55.47% -49.37% SAB Biotherapeutics -1,450.14%-94.04%-65.68% SummaryRegulus Therapeutics beats SAB Biotherapeutics on 10 of the 14 factors compared between the two stocks. Ad Porter & CompanyBanking failure dead aheadIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SABS vs. The Competition Export to ExcelMetricSAB BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.81M$3.14B$5.50B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E RatioN/A12.03116.1015.23Price / Sales15.99400.761,496.2597.74Price / CashN/A149.0039.7434.10Price / Book0.624.024.775.07Net Income-$42.19M-$42.25M$119.06M$225.46M7 Day Performance40.07%8.04%0.80%0.37%1 Month Performance49.81%8.69%5.65%3.57%1 Year Performance288.00%32.09%36.75%29.43% SAB Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SABSSAB Biotherapeutics2.6412 of 5 stars$3.88+19.0%$12.40+219.6%+288.0%$35.81M$2.24M0.00140Negative NewsHigh Trading VolumeRGLSRegulus Therapeutics2.7068 of 5 stars$1.47+0.7%$10.80+634.7%+21.1%$96.24MN/A-1.1730Analyst ForecastNews CoverageGap UpAGENAgenus3.8143 of 5 stars$4.24+1.0%$10.50+147.6%-75.6%$91.46M$156.31M-0.37389Upcoming EarningsShort Interest ↑FBIOFortress Biotech2.8545 of 5 stars$1.92+0.8%$13.00+578.9%+13.1%$43.68M$84.51M-0.59186BOLTBolt Biotherapeutics2.703 of 5 stars$0.66+4.0%$3.50+430.4%-33.2%$25.25M$11.17M-0.38100Gap UpCRISCuris3.0834 of 5 stars$4.18-2.3%$26.00+522.0%-11.3%$25.00M$10.02M-0.5149Upcoming EarningsAnalyst ForecastShort Interest ↓News CoverageMTEMMolecular Templates1.673 of 5 stars$0.45+0.0%N/A-90.8%$2.96M$57.31M-0.1762Negative NewsAMGNAmgen4.5954 of 5 stars$320.100.0%$333.50+4.2%+22.4%$172.00B$28.19B40.9926,700Earnings ReportDividend AnnouncementAnalyst ForecastAnalyst RevisionVRTXVertex Pharmaceuticals3.4628 of 5 stars$472.52-0.7%$492.50+4.2%+27.6%$121.96B$9.87B-232.775,400Upcoming EarningsAnalyst ForecastGILDGilead Sciences4.9367 of 5 stars$88.90+0.1%$86.85-2.3%+11.6%$110.68B$27.12B108.4118,000Upcoming EarningsAnalyst ForecastREGNRegeneron Pharmaceuticals4.8472 of 5 stars$841.04+0.3%$1,101.00+30.9%+6.6%$92.72B$13.12B22.2713,450Analyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies RGLS Competitors AGEN Competitors FBIO Competitors BOLT Competitors CRIS Competitors MTEM Competitors AMGN Competitors VRTX Competitors GILD Competitors REGN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SABS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
